Table 6. Clinical trials evaluating TLR5 and polyTLR agonists in oncological indications*.
| Compound | Indication | Trials | Phase | Status | Notes | Ref. |
|---|---|---|---|---|---|---|
| CBLB502 |
Adult solid tumors |
1 |
I |
Recruiting |
As single agent |
NCT01527136 |
| CADI-05 |
Bladder cancer |
2 |
I |
Completed |
As single agent |
NCT00694798 |
| II |
Active, not recruiting |
As single agent |
NCT00694915 |
|||
| Melanoma |
1 |
I/II |
Terminated |
As single agent |
NCT00675727 |
|
| NSCLC |
1 |
II |
Completed |
Combined with cisplatin and paclitaxel |
NCT00680940 |
|
| Prostate cancer |
1 |
II |
Terminated |
Combined with docetaxel |
NCT00525408 |
|
| IMM-101 | Colorectal cancer |
1 |
II |
Recruiting |
Combined with SBRT |
NCT01539824 |
| Melanoma |
2 |
I |
Completed |
As single agent |
NCT01308762 |
|
| I/II |
Enrolling by invitation |
As single agent |
NCT01559818 |
|||
| Pancreatic cancer | 1 | II | Recruiting | Combined with gemcitabine | NCT01303172 |
Abbreviations: NSCLC, non-small cell lung carcinoma; SBRT, stereotactic body radiotherapy. *Started after January, 1st 2008.